LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Guardant Health Inc

Fechado

SetorSaúde

103.29 -2.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

99.21

Máximo

103.59

Indicadores-chave

By Trading Economics

Rendimento

7.2M

-93M

Vendas

33M

265M

Margem de lucro

-34.965

Funcionários

1,999

EBITDA

6.6M

-82M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+28.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.6B

14B

Abertura anterior

105.66

Fecho anterior

103.29

Sentimento de Notícias

By Acuity

50%

50%

141 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Guardant Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de fev. de 2026, 23:55 UTC

Conversa de Mercado

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 de fev. de 2026, 23:53 UTC

Conversa de Mercado

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 de fev. de 2026, 23:53 UTC

Conversa de Mercado

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 de fev. de 2026, 23:51 UTC

Conversa de Mercado

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 de fev. de 2026, 23:35 UTC

Conversa de Mercado

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 de fev. de 2026, 23:21 UTC

Ganhos

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 de fev. de 2026, 23:20 UTC

Ganhos

Nickel Industries 2025 Operating Profit US$126.4 Million

22 de fev. de 2026, 23:19 UTC

Ganhos

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 de fev. de 2026, 23:19 UTC

Ganhos

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 de fev. de 2026, 23:18 UTC

Ganhos

Nickel Industries Won't Pay a Final Dividend

22 de fev. de 2026, 23:16 UTC

Ganhos

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 de fev. de 2026, 21:35 UTC

Ganhos

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 de fev. de 2026, 21:34 UTC

Ganhos

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 de fev. de 2026, 21:34 UTC

Ganhos

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 de fev. de 2026, 21:33 UTC

Ganhos

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 de fev. de 2026, 21:33 UTC

Ganhos

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 de fev. de 2026, 21:28 UTC

Ganhos

Ampol Final Dividend A$0.60/Share

22 de fev. de 2026, 21:28 UTC

Ganhos

Ampol FY Revenue A$31.37 Billion, Down 10%

22 de fev. de 2026, 21:28 UTC

Ganhos

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 de fev. de 2026, 21:28 UTC

Ganhos

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 de fev. de 2026, 14:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 de fev. de 2026, 05:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

20 de fev. de 2026, 23:12 UTC

Aquisições, Fusões, Aquisições de Empresas

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 de fev. de 2026, 22:12 UTC

Ganhos

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

20 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

20 de fev. de 2026, 21:23 UTC

Ganhos

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 de fev. de 2026, 21:20 UTC

Conversa de Mercado

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 de fev. de 2026, 21:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 de fev. de 2026, 20:38 UTC

Conversa de Mercado

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparação entre Pares

Variação de preço

Guardant Health Inc Previsão

Preço-alvo

By TipRanks

28.24% parte superior

Previsão para 12 meses

Média 132.22 USD  28.24%

Máximo 175 USD

Mínimo 110 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Guardant Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

19

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

38.86 / 47.41Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

141 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat